Details of the Drug Combination

General Information of Drug Combination (ID: DCKFZ16)

• Drug Combination Name: DFN-15 + SY-1425
• Indication: Amelanotic melanoma; Status: Investigative [1]
• Component Drugs:
  DFN-15 (DM3BF9B): N.A.
  SY-1425 (DMH8UF0): N.A.
• High-throughput Screening Result:
  Testing Cell Line: M14
  Zero Interaction Potency (ZIP) Score: 1
  Bliss Independence Score: 3.36
  Loewe Additivity Score: 0.44
  LHighest Single Agent (HSA) Score: 0.14

Molecular Interaction Atlas of This Drug Combination

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

Indication(s) of SY-1425

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[3]
Myelodysplastic syndrome	2A37	Phase 1	[3]

SY-1425 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Retinoic acid receptor alpha (RARA)	TTW38KT	RARA_HUMAN	Agonist	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Colon carcinoma	DCGOOAU	KM12	Investigative	[4]
Invasive ductal carcinoma	DCYZOEB	HS 578T	Investigative	[4]
Cutaneous melanoma	DC53O5U	SK-MEL-5	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCEPIN8	OVCAR-4	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCBL4FV	OVCAR-5	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.